General MedicationsORALGeneric

TOFACITINIB CITRATE

Standard Dose

EQ 5MG BASE

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Discontinued

Summary

Approval overview TOFACITINIB CITRATE is listed in Drugs@FDA under application 209829 (ANDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient TOFACITINIB CITRATE Form and strength TABLET;ORAL - EQ 5MG BASE Sponsor ZYDUS PHARMS Submission history Latest submission status date: 2023-03-14 00:00:00.

Structured Monograph

Clinical summary

Approval overview TOFACITINIB CITRATE is listed in Drugs@FDA under application 209829 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient TOFACITINIB CITRATE Form and strength TABLET;ORAL - EQ 5MG BASE Sponsor ZYDUS PHARMS Submission history Latest submission status date: 2023-03-14 00:00:00. Submission type: ORIG.

Monitoring

• Marketing status: Discontinued
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.